Gan-Jiang-Ling-Zhu decoction improves steatohepatitis induced by choline-deficient-high-fat-diet through the METTL14/N6-methyladenosine-mediated Ugt2a3 expression
Year: 2024
Type: article
Abstract: Gan-Jiang-Ling-Zhu (GJLZ) decoction, a classical Chinese herbal prescription, can be applied for the treatment of metabolic diseases including liver steatosis. Although GJLZ decoction has been widely applied clinically for thousands of years, the mechanism of GJLZ decoction behind treatment of nonalcoholic steatohepatitis (NASH) remains relatively unelucidated. To elucidate the efficacy of GJLZ decoction in the treatment of NASH and to investigate its underlying mechanisms from an epigenetic perspective. The quality control of chemical components in GJLZ decoction was conducted. C57BL/6J mice with NASH were induced by feeding them a choline-deficient-high-fat-diet (CDHFD), along with GJLZ decoction intervention for 4 weeks. Then NASH phenotypes including histological steatosis, inflammation, hepatic apoptosis, fibrosis, serum liver enzyme and lipid level were measured. N6-methyladenosine (m 6 A) and transcriptome sequencing were performed. Levels and functions of methyltransferases and different genes were performed by quantitative polymerase chain reaction, immunofluorescence, gene knockdown, oil red O staining and western blotting. GJLZ decoction significantly reduced liver weight, liver index and improved hepatic steatosis, and inflammation, as well as inhibited hepatic apoptosis and fibrosis. Moreover, GJLZ decoction significantly reduced the levels of lactate dehydrogenase, aminotransferase, triglyceride, aspartate aminotransferase, and inhibited levels of interleukin 6 and tumor necrosis factor α. Transcriptome and m 6 A sequencing revealed the landscape of transcriptome and m 6 A modification influenced by NASH and the following GJLZ decoction intervention. Eleven differential genes were identified, and GJLZ markedly promoted m 6 A level of UDP glucuronosyltransferase family 2 member A3 (Ugt2a3), to promote its expression. Additionally, GJLZ significantly promoted methyltransferase 14 (METTL14) expression, whereas METTL14 knockdown aggravated hepatocellular steatosis. Finally, METTL14 knockdown significantly reduced the level of Ugt2a3 by promoting its degradation, whereas, Ugt2a3 overexpression could markedly inhibit hepatocellular steatosis. GJLZ decoction demonstrates potential in alleviating CDHFD-induced NASH by modulating the METTL14-m 6 A-Ugt2a3 axis, offering a novel therapeutic approach for NASH treatment. • GJLZ decoction significantly ameliorates hepatic inflammation and steatosis in CDHFD-induced mice. • GJLZ decoction significantly increased m 6 A level of Ugt2a3, to promote Ugt2a3 expression. • Knockdown of METTL14 aggravated hepatocellular steatosis and decreased Ugt2a3 expression by promoting its degradation. • GJLZ decoction alleviated CDHFD-induced NASH by modulating the METTL14-m 6 A-Ugt2a3 axis.
Source: Journal of Ethnopharmacology
Authors: Jiaxuan Wu, Sijing Xian, Shengan Zhang, Yunuo Yang, Jiashu Pan, Wenjun Zhou, Dan Hu, Guang Ji, Yanqi Dang
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $3,610
OpenAlex ID: W4404635758
